Repeated adrenaline doses and survival from an out-of-hospital cardiac arrest.


Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 05 2018
revised: 24 12 2018
accepted: 17 01 2019
pubmed: 2 2 2019
medline: 28 7 2020
entrez: 2 2 2019
Statut: ppublish

Résumé

Adrenaline is the primary drug of choice for resuscitation from out-of-hospital cardiac arrest (OHCA). Although adrenaline may increase the chance of achieving return of spontaneous circulation (ROSC), there is limited evidence that repeated doses of adrenaline improves overall survival, and increasing evidence of a detrimental effect on neurological function in survivors. This paper reports the relationship between repeated doses of adrenaline and survival in a cohort of patients attended by the London Ambulance Service in the United Kingdom. A retrospective review of OHCA treated by the London Ambulance Service over a one year period. Patients aged ≥18 years who received one or more doses of adrenaline (1 mg bolus) during resuscitation were included in the analyses. Outcomes described are survival to hospital discharge and survival to one year post-arrest. Over the one year study period, 3151 patients received adrenaline during OHCA. A significant inverse relationship was found between increasing cumulative doses of adrenaline and survival both to hospital discharge and one year post-arrest. No patients survived after receiving more than ten adrenaline doses. Our study indicates that repeated doses of adrenaline are associated with decreasing odds of survival. There were no survivors amongst patients requiring more than 10 doses of adrenaline.

Sections du résumé

BACKGROUND
Adrenaline is the primary drug of choice for resuscitation from out-of-hospital cardiac arrest (OHCA). Although adrenaline may increase the chance of achieving return of spontaneous circulation (ROSC), there is limited evidence that repeated doses of adrenaline improves overall survival, and increasing evidence of a detrimental effect on neurological function in survivors. This paper reports the relationship between repeated doses of adrenaline and survival in a cohort of patients attended by the London Ambulance Service in the United Kingdom.
METHODS
A retrospective review of OHCA treated by the London Ambulance Service over a one year period. Patients aged ≥18 years who received one or more doses of adrenaline (1 mg bolus) during resuscitation were included in the analyses. Outcomes described are survival to hospital discharge and survival to one year post-arrest.
RESULTS
Over the one year study period, 3151 patients received adrenaline during OHCA. A significant inverse relationship was found between increasing cumulative doses of adrenaline and survival both to hospital discharge and one year post-arrest. No patients survived after receiving more than ten adrenaline doses.
CONCLUSION
Our study indicates that repeated doses of adrenaline are associated with decreasing odds of survival. There were no survivors amongst patients requiring more than 10 doses of adrenaline.

Identifiants

pubmed: 30708076
pii: S0300-9572(19)30007-3
doi: 10.1016/j.resuscitation.2019.01.022
pii:
doi:

Substances chimiques

Vasoconstrictor Agents 0
Epinephrine YKH834O4BH

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

316-321

Subventions

Organisme : Department of Health
ID : 12/127/126
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Rachael T Fothergill (RT)

Clinical Audit and Research Unit, London Ambulance Service NHS Trust, London, United Kingdom; Warwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, United Kingdom. Electronic address: rachael.fothergill@lond-amb.nhs.uk.

Amber C Emmerson (AC)

Clinical Audit and Research Unit, London Ambulance Service NHS Trust, London, United Kingdom.

Rajeshwari Iyer (R)

Clinical Audit and Research Unit, London Ambulance Service NHS Trust, London, United Kingdom.

Johanna Lazarus (J)

Clinical Audit and Research Unit, London Ambulance Service NHS Trust, London, United Kingdom.

Mark Whitbread (M)

Medical Directorate, London Ambulance Service NHS Trust, London, United Kingdom.

Jerry P Nolan (JP)

Bristol Medical School, University of Bristol, Bristol, BS8 1TH, United Kingdom; Royal United Hospital, Bath, BA3 1NG, United Kingdom; Warwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, United Kingdom.

Charles D Deakin (CD)

Respiratory BRU, University Hospital Southampton, SO16 6YD, United Kingdom; South Central Ambulance Service NHS Foundation Trust, Otterbourne, United Kingdom.

Gavin D Perkins (GD)

Warwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH